Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Long-term remission with venetoclax plus azacitidine in acute myeloid leukemia with negative conversion of FLT3 companion diagnostic testing at relapse].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2026

Yoshihara Satsuki, Toya Takashi, Handa Tomoyuki, Ogawa Seishi, Mitani Kinuko, Imai Yoichi

Abstract excerpt

An 80-year-old man was diagnosed with acute myeloid leukemia (AML), and molecular analysis identified FLT3-ITD, TKD mutations. Induction chemotherapy with daunorubicin plus cytarabine achieved hematological complete remission; however, extramedullary infiltration was detected in the skin and central nervous system. Due to this extramedullary disease, treatment with mitoxantrone plus high-dose cytarabine was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Recurrence

Share to Remission Induction

Share to Sulfonamides

Source

Identifiers

PMID: 42543635
DOI: 10.11406/rinketsu.67.691

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Long-term remission with venetoclax plus azacitidine in acute myeloid leukemia with negative conversion of FLT3 companion diagnostic testing at relapse].PMID 42543635Read ↗

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemiaSemantic proximity Read ↗

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.Semantic proximity Read ↗

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.Semantic proximity Read ↗

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trialSemantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 MutationsSemantic proximity Read ↗

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.Semantic proximity Read ↗

[Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].Semantic proximity Read ↗

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AMLSemantic proximity Read ↗

[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review].Semantic proximity Read ↗

Effective Treatment with Venetoclax and Hypomethylating Agents for the Coexistence of Multiple Myeloma and Acute Myeloid Leukemia: A Case Report and Literature Review.Semantic proximity Read ↗

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.